First Trust Mid Cap Core AlphaDEX Fund (FNX)
Live price chart, market sentiment, and community perspectives for First Trust Mid Cap Core AlphaDEX Fund (NASDAQ: FNX).
Live price chart, market sentiment, and community perspectives for First Trust Mid Cap Core AlphaDEX Fund (NASDAQ: FNX).
On our trading desk, we are evaluating FNX's recent sentiment readings hovering around a neutral 45-50% range. While the broader news flow feels mildly defensive, the underlying valuation discount with a P/E of 13.13x compared to the category average near 17x provides an interesting setup for value-oriented managers looking for tactical mid-cap exposure without chasing expensive large-cap names.
When reviewing quantitative factor performance, note that the Nasdaq AlphaDEX methodology ranks eligible stocks from the Nasdaq US 600 Mid Cap Index on both growth factors (price appreciation, sales-to-price, sales growth) and value factors (book value-to-price). However, this active quantitative rotation leads to a heavy 96% portfolio turnover, which introduces significant tax drag for taxable accounts.
As a quant analyst looking at liquidity and friction, I note that FNX manages around $1.4 billion in market cap, but its average daily volume can be relatively thin, paired with a 0.19% bid-ask spread. Furthermore, short interest dropped sharply by over 51% in June down to just 0.11% of the public float, suggesting that short-term bearish bets have largely evaporated.
From a risk management standpoint, FNX presents notable concerns. The fund runs hotter than its peers with a 5-year beta of 1.10 and a 3-year standard deviation of 17.5%. More concerning is the 10-year downside capture of 123, which indicates that the fund tends to drop harder during sharp market selloffs without consistently delivering a higher risk-adjusted return across 3- and 5-year windows.
Evaluating the structural fee drag, FNX carries an expense ratio of 0.62%. When stacked against standard passive mid-cap blend alternatives, this cost is several times higher. Combined with the high turnover and trading frictions, investors are paying a premium fee for an enhanced index strategy that has not consistently outperformed its baseline category risks.
Explore plasma cleansing, somatic organ swaps, and BCI.